TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Authors
Category Primary study
ConferenceGut
Year 2024
This article has no abstract
Epistemonikos ID: c84db83de66af0ad1fd590f070086ab026d349cd
First added on: Apr 30, 2026